Subject Area and Research Team: VIII. Optimization of cancer management

Subject Area and Research Team: VIII. Optimization of cancer management


Research topics

1. Childhood malignancies. Optimization of cancer care. Nutritional status of children with cancer and childhood cancer survivors. Standardization of surgical treatment

2. Breast cancer. Increasing quality of life and treatment efficacy. Focus on special breast cancer populations The impact of physical activity on treatment outcomes

3. Lung cancer. Innovative systemic therapies

4. Brain metastases. Novel therapeutic approaches based on biological knowledge

5. Body composition parameters. Prognostic value of sarcopenia in childhood malignancies. Cancer-associated cachexia in lung cancer

Coordinators

Coordinator #1 Coordinator #2
Name and surname
prof._Jassem.jpg
Jacek Jassem
prof._dr_hab._Ewa_Bień.jpg
Ewa Bień
Academic degree Prof. Dr. Habil. Prof. Dr. Habil.
Employment unit Department of Oncology & Radiotherapy Department of Paediatrics, Haematology & Oncology
Polish Platform of Medical Research Prof. Dr. Habil. Jacek Jassem Prof. Dr. Habil. Ewa Bień
Email jacek.jassem@gumed.edu.pl ewa.bien@gumed.edu.pl
Phone number +48 58 349 45 10 +48 58 349 28 70

photo Paweł Sudara/MUG


Research Team: VIII. Optimization of cancer management

Team Members: VIII. Optimization of cancer management (178 KB)


Feel free to contact one of our coordinators to join our Research Team.

Key current projects

1. Body composition analyses and its prognostic significance in NSCLC patients

2. Genomic characterization of brain metastases in lung cancer, breast cancer and ovarian cancer

3. Generation of updated recommendations on the use of orthotopic liver transplantation vs. aggressive resection for locally advanced hepatoblastoma

4. Standardization of methods of assessing the quality of surgical treatment of solid tumours in children

5. Paediatric rare tumours, European registry for very rare tumours in children, management of VRT in various EU countries, integration of widening EU countries

Key grants

Funding agency/grant number Title of the project Years
1. Rosetrees Trust / M 781 Cancer-associated cachexia in lung cancer 2018-2021
2. Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) – 3rd Health EU Programme/HP-PJ-06-2016 European Reference Network (ERN)-PAEDCAN Paediatric Rare Tumours Network – European Registry 2017-2021
3. Polish National Science Centre; SONATA12; grant 2016/23/D/NZ2/02890 Molecular profiles of brain metastases in lung cancer 2016-ongoing
4. Polish National Science Centre, grant 2017/25/B/NZ5/00656 A clinicopathological analysis of breast cancer with single hormone receptor positive phenotype including a quantitative evaluation of oestrogen and progesterone receptor expression and microRNA expression profile 2018-ongoing
5. COST CA19138 Lobular Breast Cancer: Discovery Science, Translational Goals, Clinical Impact (LOBSTERPOT) 2020-ongoing
6. European Commission/ Horizon 2020 programme project No. 668596 ChiLTERN – Children’s Liver Tumour European Research Network 2016-2021
7. ABM-SEK-1292/2020/WFK/ŁB Cyclin dEpendent kinase in tRiple nEGatIVe brEast canceR – a “window of opportunity” study (CAREGIVER) 2020-ongoing

International cooperation

Foreign partner (unit name) Principal investigator(s) Area of cooperation
1. Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA Patricia Steeg, Priscilla Brastianos Genomic characterization of brain metastases
2. University of Harvard, Dana Farber Cancer Institute, Radiation Oncology Hugo Aerts Body composition analyses and its prognostic significance in NSCLC patients
3. European Cooperative Study Group on Pediatric Rare Tumors (EXPeRT) Andrea Ferrari, Gianni Bisogno, Italy, Dominik Schneider, Ines Brecht, Germany, Daniel Orbach, Yves Requerre, France European registry for very rare tumors in children
4. Oncologia/Hematologia Pediatrica Hospital Universitario de Cruces, Spain, Vascular Anomalies Center, la Paz Hospital, University of Madrid, Spain, Cooperative Weichteilsarkom Studiengruppe trial, Stuttgart, Germany Ricardo Lopez-Almaraz ,Juan-Carlos Lopez-Guthierrez, Monika Sparber-Sauer, Ewa Koscielniak Vascular tumours in children
5. University College London, Cancer Institute Charles Swanton Gene expression prognostic test for patients with early stage NSCLC
6. Univesity of Cambridge, Wellcome-MRC Institute of Metabolic Science Stephen O’Rahilly GDF15 cytokine as a marker of body weight and adipose tissue compartment loss at lung cancer recurrence
7. Chalmers University of Technology, Sweden Jens Nielsen, Francesco Gatto Glycosaminoglycan profiling as non-invasive biomarkers for early stage breast cancer – a pilot study
POB_1__RT_8.png

Key publications

1. Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z, Geater S, Özgüroğlu M, Zou W, Sandler A, Enquist I, Komatsubara K, Deng Y, Kuriki H, Wen X, McCleland M, Mocci S, Jassem J, Spigel DR. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med. 2020; vol. 383: p.1328-1339.

2. Carrillo-Reixach J, Torrens L, Simon-Coma M, Royo L, Domingo-Sàbat M, Abril-Fornaguera J, Akers N, Sala M, Ragull S, Arnal M, Villalmanzo N, Cairo S, Villanueva A, Kappler R, Garrido M, Guerra L, Sábado C, Guillén G, Mallo M, Piñeyro D, Vázquez-Vitali M, Kuchuk O, Mateos ME, Ramírez G, Santamaría ML, Mozo Y, Soriano A, Grotzer M, Branchereau S, de Andoin NG, López-Ibor B, López-Almaraz R, Salinas JA, Torres B, Hernández F, Uriz JJ, Fabre M, Blanco J, Paris C, Bajčiová V, Laureys G, Masnou H, Clos A, Belendez C, Guettier C, Sumoy L, Planas R, Jordà M, Nonell L, Czauderna P, Morland B, Sia D, Losic B, Buendia MA, Sarrias MR, Llovet JM, Armengol C. Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications. J Hepatol. 2020; vol. 73: p. 328-341.

3. Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 2017; vol. 377: p. 523-533.

4. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T; ALEX Trial Investigators. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017; vol. 377: p. 829-838.

5. Meyers RL, Maibach R, Hiyama E, Häberle B, Krailo M, Rangaswami A, Aronson DC, Malogolowkin MH, Perilongo G, von Schweinitz D, Ansari M, Lopez-Terrada D, Tanaka Y, Alaggio R, Leuschner I, Hishiki T, Schmid I, Watanabe K, Yoshimura K, Feng Y, Rinaldi E, Saraceno D, Derosa M, Czauderna P. Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children’s Hepatic tumors International Collaboration. Lancet Oncol. 2017; vol. 18: p. 122-131.

6. Gril B, Paranjape AN, Woditschka S, Hua E, Dolan EL, Hanson J, Wu X, Kloc W, Izycka-Swieszewska E, Duchnowska R, Pęksa R, Biernat W, Jassem J, Nayyar N, Brastianos PK, Hall OM, Peer CJ, Figg WD, Pauly GT, Robinson C, Difilippantonio S, Bialecki E, Metellus P, Schneider JP, Steeg PS. Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases. Nat Commun. 2018; vol. 9: p. 2705.